Access Statistics for Darius Lakdawalla

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Aging and the Growth of Long-Term Care 0 1 1 31 0 1 8 152
Aging and the Growth of Long-Term Care 0 0 0 243 0 0 21 1,315
An Economic Evaluation of the War on Cancer 0 0 0 97 1 2 15 376
Are the Young Becoming More Disabled? 0 0 0 93 0 0 9 355
Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk-Transfer 0 0 1 153 0 1 19 563
Does Medicare Benefit the Poor? New Answers to an Old Question 0 0 0 67 0 0 9 388
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? 0 0 0 23 0 0 9 49
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? 0 0 0 85 3 3 12 48
Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey 0 0 0 55 0 0 9 266
Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn? 0 0 0 6 1 4 22 67
Effects of expanding health screening on treatment – What should we expect? What can we learn? 0 0 0 6 2 2 15 70
Evaluation of Medical Technologies with Uncertain Benefits 0 0 1 49 1 1 8 53
Food Prices and the Dynamics of Body Weight 0 0 0 71 1 1 13 245
GLP-1 Therapy and the Reshaping of Socioeconomic Gradients in Health 0 8 8 8 49 52 52 52
HIV Breakthroughs and Risk Sexual Behavior 0 0 0 84 0 0 10 645
Healing the Poor: The Influence of Patient Socioeconomic Status on Physician Supply Responses 0 0 0 13 1 4 16 70
Health Insurance as a Two-Part Pricing Contract 0 0 0 97 1 1 10 439
Health and Access Effects of New Drugs: Combining Experimental and Non-Experimental Data 0 0 0 52 0 0 9 201
Insurance and Innovation in Health Care Markets 0 0 1 139 0 2 23 493
Insurance, Self-Protection, and the Economics of Terrorism 0 0 0 289 2 6 18 907
Insurer Bargaining and Negotiated Drug Prices in Medicare Part D 0 0 0 32 1 1 20 169
Insurers' Negotiating Leverage and the External Effects of Medicare Part D 0 0 0 14 0 0 10 108
Insurers’ Negotiating Leverage and the External Effects of Medicare Part D 0 0 0 3 3 3 20 92
Intellectual Property and Marketing 0 0 0 91 3 4 19 412
Intellectual Property and Marketing 0 0 0 0 1 2 10 17
International Differences in Longevity and Health and Their Economic Consequences 0 0 0 35 1 1 12 135
International Differences in Longevity and Health and their Economic Consequences 0 0 0 55 0 3 20 191
International Differences in Longevity and Health and their Economic Consequences 0 0 0 51 0 1 7 271
Making Everyone’s Preferences Count: A Prospect Theory Approach to Valuing Health Improvements 0 0 0 0 0 0 0 0
Mortality Risk, Insurance, and the Value of Life 0 0 0 37 0 3 39 88
Nonprofit Production 0 0 0 0 1 1 9 205
Nonprofit Production and Competition 0 0 1 301 0 5 17 1,274
Optimal Liability for Terrorism 0 0 0 40 0 1 10 225
Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D 0 0 0 24 3 4 14 110
Risk Preferences Over Health: Empirical Estimates and Implications for Healthcare Decision-Making 0 0 0 15 0 0 15 24
The Declining Quality of Teachers 0 0 0 222 0 1 22 1,722
The Effect of US COVID-19 Excess Mortality on Social Security Outlays 0 0 0 6 0 1 24 29
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 0 0 0 89 0 1 15 387
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 0 0 0 0 1 1 15 20
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 0 0 0 492 2 2 21 1,624
The Insurance Value of Medical Innovation 0 0 0 34 0 1 16 123
The Rise in Old Age Longevity and the Market for Long-Term Care 0 0 0 3 2 2 10 781
The Rise in Old Age Longevity and the Market for Long-Term Care 0 0 0 234 0 0 11 1,788
The Value of Medican and Pharmaceutical Interventions for Reducing Obesity 0 0 0 29 1 1 15 180
The Welfare Effects of Medical Malpractice Liability 0 0 0 101 1 1 10 485
The Welfare Effects of Public Drug Insurance 0 0 1 78 1 2 17 304
Time-Inconsistency and Welfare 0 0 0 79 0 0 11 390
Understanding Health Disparities Across Education Groups 0 0 2 400 1 5 18 1,721
Understanding the Economic Consequences of Shifting Trends in Population Health 0 0 0 50 1 1 13 193
Understanding the Economic Consequences of Shifting Trends in Population Health 0 0 0 36 0 0 5 116
Understanding the Economic Consequences of Shifting Trends in Population Health 0 0 0 43 0 1 11 236
Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market 0 0 0 15 1 2 16 125
Vaccine Allocation Priorities Using Disease Surveillance and Economic Data 0 0 0 3 0 0 14 30
Total Working Papers 0 9 16 4,273 86 131 793 20,329


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies 0 0 0 57 0 0 15 231
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis 0 0 1 3 1 3 20 39
A Theory of Health Disparities and Medical Technology 0 0 2 147 2 2 24 639
A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE) 0 0 0 2 0 1 14 35
A principled approach to non-discrimination in cost-effectiveness 0 0 0 0 1 3 18 20
An economic evaluation of the war on cancer 0 0 2 110 0 0 14 596
Are Biopharmaceutical Budget Caps Good Public Policy? 0 0 2 14 1 2 14 86
Are investments in disease prevention complements? The case of statins and health behaviors 0 0 0 11 1 2 13 94
Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital? 0 0 0 35 0 0 11 191
Can the ACA Improve Population Health? 0 0 0 14 0 2 15 83
Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk Transfer 0 0 1 20 0 4 22 127
Differences in health between Americans and Western Europeans: Effects on longevity and public finance 0 0 0 27 0 0 19 127
Disability Forecasts and Future Medicare Costs 0 0 1 35 0 0 8 282
Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets 1 1 1 41 1 3 16 186
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? 0 0 0 2 0 1 11 29
Does Medicare benefit the poor? 0 0 0 139 0 0 6 347
Economics of the Pharmaceutical Industry 0 0 5 317 1 2 24 729
Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA 0 0 0 3 0 3 13 33
Geographic Variation in Health Care: The Role of Private Markets 0 1 1 76 0 1 12 433
HIV Breakthroughs and Risky Sexual Behavior 0 0 0 166 1 1 12 932
HOW DOES HEALTH INSURANCE AFFECT WORKERS’ COMPENSATION FILING? 0 0 0 15 1 1 15 299
HOW DOES TERRORISM RISK VARY ACROSS SPACE AND TIME? AN ANALYSIS BASED ON THE ISRAELI EXPERIENCE 0 0 1 103 0 0 24 339
Healing the poor: The influence of patient socioeconomic status on physician supply responses 0 0 0 3 47 47 60 132
Health insurance as a two-part pricing contract 0 0 0 49 0 0 17 377
Health risk and the value of life 0 0 3 5 2 3 27 30
Health technology assessment with risk aversion in health 0 0 0 9 0 3 20 68
Innovation and the welfare effects of public drug insurance 0 0 1 46 0 0 8 170
Insurance, self-protection, and the economics of terrorism 0 0 0 81 1 2 12 327
Insurers’ Negotiating Leverage and the External Effects of Medicare Part D 0 0 0 16 0 0 9 147
Is nursing home demand affected by the decline in age difference between spouses? 0 0 0 26 0 0 6 331
Labor Supply and Weight 0 0 1 51 0 1 18 159
Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants 0 0 1 51 1 1 9 195
Pharmaceutical advertising and Medicare Part D 0 0 1 13 0 0 18 166
Predicting quantity and quality of life with the Future Elderly Model 0 0 0 2 0 0 12 25
Prescription drug advertising and drug utilization: The role of Medicare Part D 1 1 2 5 2 2 31 49
Public Financing and the Market for Long-Term Care 0 0 0 24 0 0 8 107
Public-Private Partnership as a Path to Affordable Healthcare in Emerging Markets 0 0 0 15 0 0 11 108
Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection 0 0 0 41 0 0 9 165
Risk preferences over health: Empirical estimates and implications for medical decision-making 0 0 1 2 1 3 24 31
Social insurance and the design of innovation incentives 0 0 1 21 0 0 14 101
The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 0 0 0 72 0 0 14 310
The Economics of Teacher Quality 0 0 0 6 0 0 11 234
The Fiscal Consequences of Trends in Population Health 0 0 1 16 0 0 10 77
The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model for Measuring the Value of Gains in Health: An Exact Formulation 1 1 1 4 1 2 16 39
The Labor Market Value of Health Improvements 0 0 0 45 0 0 13 166
The Rise in Old-Age Longevity and the Market for Long-Term Care 0 0 0 106 2 3 17 462
The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinson’s Disease Population 0 0 0 2 0 1 12 34
The Value of Diagnostic Testing in Personalized Medicine 0 0 1 61 1 1 7 231
The economics of alternative payment models for pharmaceuticals 0 1 1 10 0 3 15 54
The growth of obesity and technological change 0 0 0 32 2 2 35 171
The insurance value of medical innovation 0 0 1 43 1 4 23 201
The nonprofit sector and industry performance 0 1 5 261 0 4 35 743
The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions 0 0 0 4 0 0 14 63
The value of medical and pharmaceutical interventions for reducing obesity 0 0 0 15 0 1 11 108
The welfare effects of medical malpractice liability 0 0 0 15 0 1 19 170
Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market* 0 0 1 1 0 0 15 27
Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA 0 0 0 26 0 0 9 110
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices 1 1 2 3 2 5 25 31
Want More Value from Prescription Drugs? We Need to Let Prices Rise and Fall 0 0 0 1 0 2 12 29
Welfare-Enhancing Technological Change and the Growth of Obesity 0 0 0 152 0 0 14 443
Total Journal Articles 4 7 41 2,672 73 122 980 12,268


Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Disability Forecasts and Future Medicare Costs 0 0 0 23 0 0 10 118
Economics of Obesity 0 0 3 28 2 2 15 107
Economics of Obesity 0 0 1 38 0 0 10 110
Food Prices and the Dynamics of Body Weight 0 0 1 15 0 0 15 87
Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products 0 0 3 104 1 1 13 271
Medical Care Output and Productivity in the Nonprofit Sector 0 0 0 12 2 2 12 75
Patents, innovation, and the welfare effects of Medicare Part D 0 0 0 0 0 1 10 12
Public Financing and the Market for Long-Term Care 0 0 0 8 1 1 10 62
Total Chapters 0 0 8 228 6 7 95 842


Statistics updated 2026-09-10